Boy, has GLFD ever taken a beating! A casual observer would think that Asian markets figure heavily in its bottom line calculation :-).
And, say, didn't we sign a deal, a short time ago, with Amgen? And, come to think of it, wasn't it for beaucoup bucks? You certainly wouldn't be able to determine as much from the stock price, of late. $23 per share is just plain silly. GLFD was higher than that when the "blockbuster" neuroimmunophilin deal was released, for crying out loud!
I'm annoyed for one reason, and one reason only: GLFD is practically being given away -- it is, pretty much, the biggest bargain I can find (although LGND also comes to mind,) -- and I do not have the margin capacity to increase my position! Sometimes, life can be so unfair! :-)
See you guys in the 30's,
RB |
